Evaluating the Safety and Effectiveness of Empagliflozin (Empiget™) in Type-2 Diabetes Patients: A Post-Marketing Surveillance Study in Sri Lanka

Objective: To evaluate the realworld safety, and effectiveness of empagliflozin in Sri Lankan patients with Type-2 diabetes mellitus (T2DM).Methodology: This was a prospective, multicenter, observational cohort study conducted as post-marketing surveillance at two outpatient clinical sites in Sri Lanka from January 2023 to May 2025. Adults aged 18–65 years with T2DM, HbA1c 7–10%, eGFR >60 mL/min/1.73 m², and inadequate glycemic control despite oral antidiabetic therapy were enrolled. The decision to initiate empagliflozin (Empiget™) 10 mg once daily as add-on therapy was made independently by the treating physician as part of routine clinical care and was not assigned by the study protocol. Data were collected prospectively using an electronic case report form at baseline and at 1-, 3-, and six-months follow-up visits. A non-probability consecutive sampling technique was used. Ethical approval was obtained from the institutional ethics committee of the National Hospital of Sri Lanka, and written informed consent was obtained from all participants. Safety outcomes included adverse events, serious adverse events, and treatment discontinuation, while effectiveness outcomes included changes in HbA1c, fasting blood glucose, body weight, and blood pressure.Results: Among 246 patients (mean age 51.8 ± 9.2 years), empagliflozin was generally well tolerated. Adverse events were infrequent and occurred mainly during the early treatment period, most commonly mild hypoglycemia and genitourinary symptoms. Two serious adverse events were reported, both resulting in treatment discontinuation; neither was assessed as causally related to empagliflozin. No serious adverse events were observed at six months. Median HbA1c decreased from 8.9% to 7.4%, fasting blood glucose from 159 to 121 mg/dL, body weight decreased by approximately two kg, and both systolic and diastolic blood pressure showed modest reductions. Renal function parameters remained clinically stable throughout followup.Conclusion: In this realworld postmarketing surveillance study, empagliflozin 10 mg demonstrated a favorable safety and tolerability profile and was associated with improvements in glycemic control, body weight, and blood pressure over six months.

Authors

Institutions

Publication Details

Journal
Pakistan Journal of Medical Sciences
Published
2026-11-19
DOI
https://doi.org/10.12669/pjms.42.12.20368
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluating the Safety and Effectiveness of Empagliflozin (Empiget™) in Type-2 Diabetes Patients: A Post-Marketing Surveillance Study in Sri Lanka

Sivatharshya Pathmanathan, T G Athukorala, Manilka Sumanatilleke, Charles Antonypillai et al.
Pakistan Journal of Medical Sciences
Diabetes Treatment and Management
article

Evaluating the Safety and Effectiveness of Empagliflozin (Empiget™) in Type-2 Diabetes Patients: A Post-Marketing Surveillance Study in Sri Lanka

Sivatharshya Pathmanathan, T G Athukorala, Manilka Sumanatilleke, Charles Antonypillai, Jahanzeb Kamal Khan, N. Pathirana, Mahisha Chandrasekaran, G. M. Gajaweera, Lasanthi Rangani Bhagya Dharmasiri, Jeewashini Rathnayake
article en

Abstract

Objective: To evaluate the realworld safety, and effectiveness of empagliflozin in Sri Lankan patients with Type-2 diabetes mellitus (T2DM).Methodology: This was a prospective, multicenter, observational cohort study conducted as post-marketing surveillance at two outpatient clinical sites in Sri Lanka from January 2023 to May 2025. Adults aged 18–65 years with T2DM, HbA1c 7–10%, eGFR >60 mL/min/1.73 m², and inadequate glycemic control despite oral antidiabetic therapy were enrolled. The decision to initiate empagliflozin (Empiget™) 10 mg once daily as add-on therapy was made independently by the treating physician as part of routine clinical care and was not assigned by the study protocol. Data were collected prospectively using an electronic case report form at baseline and at 1-, 3-, and six-months follow-up visits. A non-probability consecutive sampling technique was used. Ethical approval was obtained from the institutional ethics committee of the National Hospital of Sri Lanka, and written informed consent was obtained from all participants. Safety outcomes included adverse events, serious adverse events, and treatment discontinuation, while effectiveness outcomes included changes in HbA1c, fasting blood glucose, body weight, and blood pressure.Results: Among 246 patients (mean age 51.8 ± 9.2 years), empagliflozin was generally well tolerated. Adverse events were infrequent and occurred mainly during the early treatment period, most commonly mild hypoglycemia and genitourinary symptoms. Two serious adverse events were reported, both resulting in treatment discontinuation; neither was assessed as causally related to empagliflozin. No serious adverse events were observed at six months. Median HbA1c decreased from 8.9% to 7.4%, fasting blood glucose from 159 to 121 mg/dL, body weight decreased by approximately two kg, and both systolic and diastolic blood pressure showed modest reductions. Renal function parameters remained clinically stable throughout followup.Conclusion: In this realworld postmarketing surveillance study, empagliflozin 10 mg demonstrated a favorable safety and tolerability profile and was associated with improvements in glycemic control, body weight, and blood pressure over six months.

Pakistan Journal of Medical SciencesVol. 42(12)
Teaching Hospital Kandy (LK), National Hospital of Sri Lanka (LK)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon